Maurice Manning

Maurice Manning's AcademicInfluence.com Rankings

Maurice Manning

Philosophy

#10397

World Rank

#14248

Historical Rank

Logic

#7270

World Rank

#8977

Historical Rank

philosophy Degrees

Maurice Manning

Biology

#14209

World Rank

#17906

Historical Rank

Biochemistry

#2499

World Rank

#2658

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Maurice Manning's Degrees

PhD Biochemistry Stanford University
Doctorate Medicine Stanford University

Why Is Maurice Manning Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Maurice Manning's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin. (1980) (421)
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics (2012) (363)
Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. (2010) (313)
Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. (1986) (274)
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. (2008) (266)
The Importance of Vasopressin in the Development and Maintenance of DOC‐Salt Hypertension in the Rat (1979) (261)
125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand. (1988) (234)
Discovery, development, and some uses of vasopressin and oxytocin antagonists. (1989) (163)
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. (1995) (161)
Vasopressor receptor antagonist prevents behavioural effects of vasopressin (1981) (157)
Functional Selective Oxytocin-derived Agonists Discriminate between Individual G Protein Family Subtypes* (2011) (137)
Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity. (1974) (117)
Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors. (1978) (116)
Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding (2006) (113)
Design and synthesis of potent in vivo antagonists of oxytocin. (2009) (113)
Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. (1981) (113)
Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. (2007) (110)
Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. (1968) (109)
Vascular effects of arginine vasopressin during fluid deprivation in the rat. (1981) (108)
Characterization of a uterine-type oxytocin receptor in the rat hippocampus. (1983) (102)
Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. (1989) (101)
Design and uses of selective agonistic and antagonistic analogs of the neuropeptides oxytocin and vasopressin (1984) (99)
Arginine vasopressin and a vasopressin antagonist peptide: Opposite effects on extinction of active avoidance in rats (1981) (99)
Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban. (2009) (96)
Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors. (1995) (90)
Carboxy terminus of vasopressin required for activity but not binding (1984) (90)
A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors (1991) (89)
Synthesis and some pharmacological properties of [4-threonine, 7-glycine]oxytocin, [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine, 7-glycine]oxytocin (hydroxy[Thr4, Gly7]oxytocin), and [7-Glycine]oxytocin, peptides with high oxytocic-antidiuretic selectivity. (1977) (88)
Neurohypophysial peptides design of tissue-specific agonists and antagonists (1981) (88)
Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. (1993) (86)
Selective Agonists and Antagonists of Vasopressin (1987) (82)
Structural changes in the arginine vasopressin molecule that prolong its antidiuretic action. (1974) (82)
Design of potent antagonists of the vasopressor response to arginine-vasopressin. (1978) (82)
Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. (2003) (81)
The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities (1998) (80)
Selective and Potent Agonists and Antagonists for Investigating the Role of Mouse Oxytocin Receptors (2013) (79)
No requirement of cyclic conformation of antagonists in binding to vasopressin receptors (1987) (75)
Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin. (1982) (72)
Molecular pharmacology of AVP and OT receptors and therapeutic potential (1999) (68)
Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor* (1998) (66)
Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4. (1984) (63)
Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin. (1981) (63)
Oxytocin blocks enhanced motivation for alcohol in alcohol dependence and blocks alcohol effects on GABAergic transmission in the central amygdala (2019) (63)
Solid-phase synthesis of (4-threonine)-oxytocin. A more potent and specific oxytocic agent than oxytocin. (1970) (62)
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. (2002) (60)
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. (2000) (59)
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. (2007) (57)
Oxytocin receptor subtypes in the pregnant rat myometrium and decidua: pharmacological differentiations. (1993) (57)
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin. (1976) (54)
Solid phase synthesis of (1-deamino,4-valine)-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects. (1973) (54)
Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology. (2008) (53)
[1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin. (1977) (51)
Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure. (2016) (51)
Relative contribution of vasopressin and angiotensin II to the altered renal microcirculatory dynamics in two-kidney Goldblatt hypertension. (1983) (50)
Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism. (1982) (50)
The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin. (1980) (42)
Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin. (1990) (41)
[1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin. (1978) (41)
Synthetic analogs of oxytocin and the vasopressins. (1973) (38)
Synthesis and Characterization of Fluorescent Antagonists and Agonists for Human Oxytocin and Vasopressin V1a Receptors (2002) (38)
Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors. (1995) (37)
C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors. (1987) (36)
Antagonists of vasopressor and antidiuretic responses to arginine vasopressin. (1982) (36)
The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists. (1996) (36)
Discovery and design of novel and selective vasopressin and oxytocin agonists and antagonists: the role of bioassays (2000) (35)
Design of potent and selective antagonists of the vasopressor responses to arginine-vasopressin. (1982) (35)
Functional architecture of vasopressin/oxytocin receptors. (1999) (34)
Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin. (1992) (33)
The development of vasopressin antagonists. (1984) (33)
Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4. (1983) (32)
The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations (2004) (32)
Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors. (2007) (32)
Synthesis and Receptor Specificities of Vasopressin Antagonists (1986) (32)
Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. (1996) (32)
Oxytocin antagonism prevents pregnancy-associated aortic dissection in a mouse model of Marfan syndrome (2019) (31)
Novel approach to the design of synthetic radioiodinated linear V1A receptor antagonists of vasopressin. (2009) (29)
Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin. (1973) (29)
Potent V2 vasopressin antagonists with structural changes at their C-terminals (1988) (29)
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. (2004) (28)
Isolation of antibodies to the C-terminal heptapeptide of myoglobin with a synthetic peptide. (1968) (28)
A convenient method for O-alkylation of N-substituted tyrosines using a crown ether (1981) (27)
Identification of agonist binding sites of vasopressin and oxytocin receptors. (1995) (27)
Vasopressin-binding sites in the pig pituitary gland: competition by novel vasopressin antagonists suggests the existence of an unusual receptor subtype in the anterior lobe. (1994) (27)
Agonist and antagonist specificities of decidual prostaglandin-releasing oxytocin receptors and myometrial uterotonic oxytocin receptors in pregnant rats. (1994) (27)
125I‐d(CH2)5[Tyr(Me)2,Tyr(NH2)9]AVP: Iodination and binding characteristics of a vasopressin receptor ligand (1988) (26)
Design of potent and selective in vivo antagonists of the neurohypophysial peptides. (1983) (26)
Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban (2005) (25)
Design of neurohypophyseal peptides that exhibit selective agonistic and antagonistic properties. (1977) (24)
Synthetic antagonists of in vivo responses by the rat uterus to oxytocin. (1979) (24)
Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin. (2009) (24)
Receptor‐Specific Antagonists of Vasopressin and Oxytocin (1993) (23)
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. (2007) (23)
Vasopressin in the rat with partial nephrectomy-salt hypertension. (1981) (23)
Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue (2003) (23)
Position Three in Vasopressin Antagonist Tolerates Conformationally Restricted and Aromatic Amino Acid Substitutions: A Striking Contrast with Vasopressin Agonists (1997) (22)
The use of antagonists of vasopressin in studies of its physiological functions. (1985) (22)
An exploration of the effects of L‐ and D‐tetrahydroisoquinoline‐3‐carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin (1995) (21)
Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. (2008) (20)
Design of Oxytocin Antagonists, which are more Selective than Atosiban (2001) (20)
Neuroanatomical distribution and function of the vasopressin V1B receptor in the rat brain deciphered using specific fluorescent ligands. (2017) (19)
4-Proline analogues of neurohypophysial hormones: hypothetical intermediates in peptide evolution. (1969) (19)
[1-Deaminopenicillamine,4-threonine]oxytocin, a potent inhibitor of oxytocin. (1978) (19)
Solid-phase syntheis and some pharmacological properties of [8-phenylalanine]-oxytocin. (1969) (19)
Design of oxytocin antagonists, which are more selective than atosiban. (2001) (18)
Design of cyclic and linear peptide antagonists of vasopressin and oxytocin: current status and future directions (1993) (18)
Iodination of vasopressin analogues with agonistic and antagonistic properties: effects on biological properties and affinity for vascular and renal vasopressin receptors. (1987) (17)
Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors. (1997) (17)
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors. (2011) (16)
Solid-phase synthesis and some pharmacological properties of deamino-4-threonine analogs of the vasopressins and vasotocin and (deamino)arginine-vasotocin. (1973) (16)
Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family. (1995) (16)
Effect of Intracerebroventricular Captopril on Vasopressin and Blood Pressure in Spontaneously Hypertensive Rats (1981) (16)
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin. (1977) (16)
The development of potent and specific vasopressin antagonists. (1988) (16)
Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors (1998) (16)
4-Threonine analogues of neurohypophysial hormones withh selectively enhanced oxytocin-like activities. (1971) (15)
POTENT AND SELECTIVE ANTAGONISTS OF THE ANTIDIURETIC RESPONSES TO ARGININE-VASOPRESSIN BASED ON MODIFICATIONS OF (1-(β-MERCAPTO-β,β-PENTAMETHYLENEPROPIONIC ACID), 2-D-ISOLEUCINE, 4-VALINE)ARGININE-VASOPRESSIN AT POSITION 4 (1984) (14)
An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally‐restricted, polar and charged amino acids (1999) (14)
Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids. (1992) (14)
Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. (2002) (13)
4-Threonine-Oxytocin: A More Active and Specific Oxytocic Agent than Oxytocin (1970) (13)
4-β-Alanine-oxytocin: An Oxytocin Analog Containing a Twenty-one-membered Disulfide Ring* (1965) (13)
Synthesis and some pharmacological properties of [4-homoserine]oxytocin. (1977) (12)
534. The preparation and some reactions of 4-formyl-l-phenylpyrazoles (1961) (12)
6-Hemi-D-cystine-oxytocin, a diastereoisomer of the posterior pituitary hormone oxytocin. (1965) (11)
Discovery and design of novel vasopressin hypotensive peptide agonists. (1999) (11)
Correction of vasopressin deficit in the lateral septum ameliorates social deficits of mouse autism model. (2020) (11)
Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin). (1976) (11)
Position 4 analogues of [deamino‐Cys1] arginine vasopressin exhibit striking species differences for human and rat V2/V1b receptor selectivity (2006) (11)
SYNTHETIC ANTAGONISTS OF IN VIVO ANTIDIURETIC AND VASOPRESSOR RESPONSES TO ARGININE-VASOPRESSIN (1981) (11)
Immunochemical studies of myoglobin with synthetic peptides. (1972) (10)
Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin. (1985) (10)
Receptor-specific antagonists of vasopressin and oxytocin. A current perspective. (1993) (10)
Experimental uses of neurohypophysial hormone analogs (1989) (10)
Synthesis and structure–activity investigation of novel vasopressin hypotensive peptide agonists (1999) (10)
(1-(β-MERCAPTO-β,β-CYCLOPENTAMETHYLENEPROPIONIC ACID),4-VALINE, 8-D-ARGININE)VASOPRESSIN, A POTENT AND SELECTIVE INHIBITOR OF THE VASOPRESSOR RESPONSE TO ARGININE-VASOPRESSIN (1978) (10)
DESIGN OF MORE POTENT ANTAGONISTS OF THE ANTIDIURETIC RESPONSES TO ARGININE-VASOPRESSIN (1982) (9)
Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists. (1995) (9)
Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective (2008) (9)
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists. (1989) (9)
EFFECTIVE ANTAGONISTS OF THE ANTIDIURETIC ACTION OF VASOPRESSIN IN RATS * (1982) (8)
Discovery of Novel Selective Hypotensive Vasopressin Peptides (1998) (8)
Elasmobranch oxytocin-like principles: comparisons with synthetic glumitocin. (1969) (7)
Probing the molecular basis of antidiuretic specificity and duration of action with synthetic peptides (1974) (7)
Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies. (2001) (7)
Structure-Activity Studies on Oxytocin and Vasopressin 1954–1976 (1977) (6)
Partial blockade of neurotensin-induced hypotension in rats by nephrectomy captopril and saralasin. Possible mechanisms (1983) (6)
Highly potent and selective Tyr-NH2 9-containing linear V1 antagonists and D-Tyr2-containing linear V2 agonists: Potential radioiodinated ligands for vasopressin receptors (1991) (6)
[1-Deaminopenicillamine, 4-Valine, 8-D-Arginine]-Vasopressin Antagonizes the Mesenteric Vasoconstrictor Response to Arginine Vasopressin in Cats 1 (1979) (5)
Design and synthesis of potent, highly selective vasopressin hypotensive agonists (2006) (5)
Invertebrate neuropeptides resembling vasotocin and some analogues: Synthesis and pharmacological properties (1990) (5)
Molecular pharmacology of vasopressin receptors (2002) (5)
Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (5)
Potent Antagonists of the Antidiuretic Responses to Arginine-Vasopressin Based on Modifications of [1(β-Mercapto-β,β-cyclopentamethylenepropionic Acid)2-D-phenylalanine,4-valine]arginine-vasopressin at Position 4. (1984) (5)
A fraction resembling oxytocin from Squalus acanthias: pharmacological comparisons with synthetic peptides. (1970) (4)
Solid phase synthesis and some pharmacoogical properties of 4-Ser-8-Gln-Oxytocin (Glumitocin) (1968) (4)
An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acidsSymbols and abbreviations are in accordance with the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (Eur. J. Biochem. 180, A9-A11, 1989) (1999) (4)
Natriuretic effect of [7-glycine]oxytocin in the presence of diuretic agents in conscious rats. (1980) (4)
Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors. (1998) (4)
DESIGN OF POTENT ANTAGONISTS OF THE VASOPRESSOR RESPONSE TO ARGININE-VASOPRESSIN (1979) (4)
Synthesis and Some Pharmacological Properties of [4-Threonine,7-glycine]oxytocin,[1-(L-2-Hydroxy-3-mercaptopropanoic acid),4-threonine, 7-glycine]oxytocin (Hydroxy[Thr4,Gly7]oxytocin), and [7-Glycine]oxytocin, Peptides with High Oxyto (1977) (4)
Solid phase synthesis of [4-proline]oxytocin, [4-proline]mesotocin, [4-proline]glumitocin, and [4-lysine]mesotocin. (1971) (4)
Identification of a Single Residue Responsible for Agonist Selectivity in the Oxytocin‐Vasopressin Receptors (1997) (3)
Identification of a single residue responsible for agonist selectivity in the oxytocin-vasopressin receptors. (1997) (3)
Design of More Potent, Radioiodinatable and Fluorescent Vasopressin Hypotensive Peptide Agonists (2001) (3)
2-O-Methyl and 2-O-éthyl-tyrosine derivatives of [8-arginine]vasopressin analogs: highly specific antidiuretic agonists (1988) (3)
1-Mercaptoacetic Acid-4-β-alanine-oxytocin* (1967) (3)
Discovery of novel selective hypotensive vasopressin peptides. A new vasodilating vasopressin receptor? (1998) (2)
SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF DEAMINO(4-THREONINE,8-D-ARGININE)VASOPRESSIN AND DEAMINO(8-D-ARGININE)VASOPRESSIN, HIGHLY POTENT AND SPECIFIC ANTIDIURETIC PEPTIDES, AND (8-D-ARGININE)VASOPRESSIN AND DEAMINO-ARGININE-V (1976) (2)
Synthesis of Posterior Pituitary Hormones and Hormone Analogs (118 Literaturangaben). (1982) (2)
The Role of the Merrifield Solid Phase Method in the Discovery and Exploration of a New Class of Selective Vasopressin Hypotensive Agonists (2007) (2)
Specificity of Agonistic and Antagonistic Analogues of Vasopressin (1984) (2)
Control of Social Withdrawal of Mice Deficient for the Autism Gene Magel2 by Restoration of Vasopressin-Oxytocin Dialogue in Septum (2019) (2)
A Surprise End to 20 Year Search for Selective Agonists for Rat Vasopressin V 1b Receptor (2006) (1)
Effects of Structural Changes on the Natriuretic Activity of Oxytocin Analogs in Conscious Rats 1 (1980) (1)
The deamino derivatives of [4-threonine]-oxytocin and [4-threonine]-mesotocin; Analogs possessing a surprising spectrum of diminished pharmacological activities (2005) (1)
Selective Agonists for the Human Vasopressin V1b Receptor are Potent Antidiuretic Agonists in the Rat (2006) (1)
Discovery of new lead for the design of antagonists of human vasopressin(VP)V1b receptor (2002) (1)
Approaches to the design of orally active linear vasopressin antagonists (1993) (1)
Synthesis and Some Pharmacological Properties of 18 Potent O-Alkyltyrosine- Substituted Antagonists of the Vasopressor Responses to Arginine-Vasopressin. (1986) (1)
(1-DEAMINOPENICILLAMINE,4-THREONINE)OXYTOCIN, A POTENT INHIBITOR OF OXYTOCIN (1978) (1)
(1-DEAMINOPENICILLAMINE,4-VALINE)-8-D-ARGININE-VASOPRESSIN, A HIGHLY POTENT INHIBITOR OF THE VASOPRESSOR RESPONSE TO ARGININE-VASOPRESSIN (1977) (1)
[Treatment of diabetes insipidus with synthetic vasopressin derivatives (effect of 1-deamino-8-D-arginine vasopressin and 1-deamino-valine-8-D-arginine vasopressin)]. (1980) (1)
DESIGN OF POTENT AND SELECTIVE ANTAGONISTS OF THE VASOPRESSOR RESPONSES TO ARGININE-VASOPRESSIN (1982) (1)
Chemical structure and biological activity of hormones and related compounds (1981) (1)
Solid phase synthesis and some pharmacological properties of 8-glutamine-oxytocin: a possible intermediate in the evolution of the neurohypophysial hormones (1969) (1)
Cyclic and linear vasopressin V1 and V1/V2 antagonists containing arginine in the 4-position (1991) (1)
SOLID-PHASE SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF 4-THREONINE ANALOGS OF VASOPRESSINS AND VASOTOCIN AND OF ARGININE-VASOPRESSIN AND ARGININE-VASOTOCIN (1973) (0)
Table of Contents (1995) (0)
SOLID-PHASE SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF DEAMINO-4-THREONINE ANALOGS OF THE VASOPRESSINS AND VASOTOCIN AND (DEAMINO)ARGININEVASOTOCIN (1973) (0)
D-Cys6 substitution in vasopressin and oxytocin antagonist design: A reassessment (1995) (0)
New pharmacological tools to investigate oxytocin receptors in neurodevelopmental brain disorders (2015) (0)
Antidiuretic effect of 1 deamino 4 valine 8 D arginine vasopressin in diabetes insipidus of various types (1975) (0)
18 – Vla Vasopressin Receptors: Studies with Radioiodinated Ligand (1993) (0)
SURPRISING FINDINGS WITH SOME DELETION-MODIFIED SELECTIVE V2 ANTAGONISTS OF ARGININE VASOPRESSIN (1987) (0)
SYNTHESIS AND SOME PHARMACOLOGICAL PROPERTIES OF (4-HOMOSERINE)OXYTOCIN (1977) (0)
SYNTH. VON (4-PROLIN)-OXYTOCIN (IIA), (4-PROLIN)-MESOTOCIN (IIB), (4-PROLIN)-GLUMITOCIN (IIC) UND (4-LYSIN)-MESOTOCIN (IID) AN FESTKOERPERN (1972) (0)
DISCIOVERY AND DESIGN OF NOVEL VASOPFESIN HYE'OTENSIW PEPTIDE AGONISTS (1999) (0)
DESIGN OF MORE POTENT AND SELECTIVE ANTAGONISTS OF THE ANTIDIURETIC RESPONSES TO ARGININE-VASOPRESSIN DEVOID OF ANTIDIURETIC AGONISM (1982) (0)
(1-(β-MERCAPTO-β,.BET (1980) (0)
Factors influencing vasopressin levels in body fluids (1985) (0)
NONOSMOTIC RELEASE AND VASCULAR EFFECTS OF VASOPRESSIN (1981) (0)
A Novel Approach to the Design and Synthesis of Radio-Iodinated Linear Antagonists of Vasopressin and Oxytocin, (1992) (0)
Effect of the vasopressin antagonist d(CH2)5 Tyr(Et)VAVP on diuresis in rat. (1984) (0)
SYNTHETIC ANTAGONISTS OF IN VIVO RESPONSES BY THE RAT UTERUS TO OXYTOCIN (1979) (0)
No requirement of cyclic conformation of antagonists in binding to vasopressin receptors (1988) (0)
An investigation of position 3 in arginine vasopressin (AVP) (2002) (0)
SOLID PHASE SYNTHESIS OF (1-DEAMINO, 4-VALINE)-8-D-ARGININE-VASOPRESSIN (DVDAVP), A HIGHLY POTENT AND SPECIFIC ANTIDIURETIC AGENT POSSESSING PROTACTED EFFECTS (1973) (0)
A radioiodinated liear vasopressin antagonist: Ligand with high affinity and specificity for V1a (1991) (0)
(1-(L-2-HYDROXY-3-MERCAPTOPROPANOIC ACID)) ANALOGS OF ARGININE-VASOPRESSIN, (8-D-ARGININE)VASOPRESSIN, AND (4-VALINE,8-D-ARGININE)VASOPRESSIN (1977) (0)
Synthesis and Some Pharmacological Properties of (1-(L-2-Hydroxy-3-mercaptopropanoic acid), 4-threonine)oxytocin (Hydroxy(4-Thr)oxytocin), a Peptide with Strikingly High Oxytocic Potency, and of (1-(L-2-Hydroxy-3-mercaptopropanoic aci (1976) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Maurice Manning?

Maurice Manning is affiliated with the following schools:

University of Toledo

Maurice Manning's Academic­Influence.com Rankings

Maurice Manning's Degrees

Why Is Maurice Manning Influential?

Maurice Manning's Published Works

Published Works

What Schools Are Affiliated With Maurice Manning?

Maurice Manning's AcademicInfluence.com Rankings